A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder
2007

Combining Atomoxetine and Methylphenidate for ADHD Treatment

Sample size: 25 publication Evidence: low

Author Information

Author(s): Gabrielle A. Carlson, David Dunn, Douglas Kelsey, Dustin Ruff, Susan Ball, Lisa Ahrbecker, Albert J. Allen

Primary Institution: Stony Brook School of Medicine

Hypothesis

Can augmenting atomoxetine with methylphenidate improve treatment outcomes in children with ADHD who did not respond adequately to stimulants?

Conclusion

Methylphenidate can be safely combined with atomoxetine, but the small sample size limits the conclusions that can be drawn.

Supporting Evidence

  • 43% of patients achieved normalization on ADHD ratings with atomoxetine treatment.
  • Atomoxetine treatment was efficacious on outcome measures.
  • No significant differences in safety measures between the augmentation groups.

Takeaway

This study looked at whether adding another medicine could help kids with ADHD who didn't get better with their first medicine. It found that the new medicine was safe to use together, but it didn't really make things better.

Methodology

Children with ADHD who previously failed stimulant treatment were given atomoxetine and then randomly assigned to receive either methylphenidate or placebo for 6 weeks.

Potential Biases

Potential bias due to the small sample size and the nature of the study design.

Limitations

The study was underpowered due to a small sample size, which limits the generalizability of the findings.

Participant Demographics

Mean age was 9.6 years; 83% were male and 83% were Caucasian.

Statistical Information

P-Value

p ≤ 0.001

Statistical Significance

p ≤ 0.001

Digital Object Identifier (DOI)

10.1186/1753-2000-1-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication